INTRODUCTION
a-Linolenic acid (ALA) has been shown by animal [1] [2] [3] [4] [5] [6] [7] [8] [9] and epidemiological studies 10, 11) to exhibit an antihypertensive effect. Blood pressure was reported to have been significantly lower in SHR administered ALA than in the controls 9) . Epidemiological studies have shown a negative correlation between ALA intake and blood pressure 10, 11) . Also, Djousse et al. 12) reported that the incidence of hypertension was significantly lower in a group with a high rather than a low ALA intake.
Although flaxseed oil is rich in ALA, it is not widely used as edible oil because of its poor flavor and susceptibility to oxidation. Takeuchi et al. developed edible oil with an excellent flavor and resistance to oxidation as well as a high ALA content using their original purification and compounding technology, and reported that this oil decreases systolic and diastolic pressures in individuals with high normal blood pressure or mild hypertension 13) . The angiotensin-converting enzyme inhibitors (ACEIs) are recommended as one of the first line drugs for treatment of hypertension 14, 15) . ACEI inhibits the generation of angiotensin II, which is a pressor factor, and degradation of bradykinin, which is a depressor factor. ACEI decreases the blood pressure by reducing the pressor factor and increasing the depressor factor. ALA has also been reported to reduce the blood pressure by increasing the circulating bradykinin concentration 9) . Therefore, the blood pressure may be reduced further by the simultaneous intake of ALA and ACEI. We, thus, evaluated the interaction between ALA-enriched oil and ACEI concerning the decrease in blood pressure using SHR. This study is important to evaluate the safety of high-ALA-containing food consumption. tion of the Prime Minister's Office in Japan). The experimental plan was approved by the Laboratory Animal Care Committee of Kagawa University.
Seven-week-old male SHR of the Izumo colony (SHR/ Izm, Japan SLC, Inc., Hamamatsu, Shizuoka, Japan) were individually housed in stainless steel wire cages and allowed free access to sterilized water. The temperature of the animal room was set at 23 1 , with a humidity of 50 5%, and illumination from 08:00 to 20:00 h. The animals were also allowed free access to a commercial stock diet (CE-2, CLEA Japan, Inc., Tokyo).
The rats, weighing 150-170 g, were randomized into 3 groups (n = 6). The rats were orally administrated 1 mL (density: 0.92 g/mL) of ALA-enriched oil (The Nisshin OilliO Group, Ltd., Tokyo, Japan) and/or 3mg/kg body weight of angiotensin-converting enzyme inhibitor (ACEI). The fatty acid composition of ALA-enriched oil is shown in . ALA-enriched oil is a mixture of rapeseed, flaxseed, and rice oils purified to an edible grade. Enalapril was used as ACEI. The systolic blood pressure was measured 4 h after oral administration. Following the measurement of systolic blood pressure, the rats were sacrificed by decapitation, and blood was collected. Serum was separated by centrifugation at 2,700 g for 15 min at 4 .
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Blood pressure was measured using a non-preheating, non-invasive blood pressure monitor for mice and rats (BP-98A, Softron Co., Ltd., Tokyo, Japan).
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The serum bradykinin level was analyzed by means of an enzyme immunoassay kit (Peninsula Laboratories Inc., San Carlos, CA, U.S.A.).
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The fatty acid composition of ALA-enriched oil was determined by a gas chromatography system (6890 series, Agilent Technologies, Inc., Santa Clarita, CA, U.S.A.) with a capillary column (TC-70, GL-Sciences Inc., Tokyo, Japan), after methylation with boron trifluoride 16) .
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The results are expressed as means standard error (SE). For comparison between before and after administration, the paired t-test was used. For comparison among the 3 groups before or after administration, Bonferroni's multiple comparison was used. Differences with a p value < 0.05 were considered significant. A statistical software package (SPSS 13.0J, SPSS Japan, Inc., Tokyo, Japan) was used for all statistical analyses.
RESULTS AND DISCUSSION
Previous study showed that ALA-enriched oil with an excellent flavor and resistance to oxidation is edible oil appropriate for individuals with high normal blood pressure or mild hypertension. ACEI is a drug widely used for the treatment of hypertension. Food components have been reported to affect the actions of drugs 17, 18) . Therefore, it is important to examine the influence of the combination of ALA and hypotensive agents and evaluate the safety of ALA ingestion. Enalapril used in this study is a typical ACEI and is frequently used in Japan as an antihypertensive agent.
shows changes in systolic pressure from before to after the administration of ALA-enriched oil and ACEI. The systolic pressure showed no significant difference among the 3 groups before the administration, but decreased significantly in all 3 groups following administration. The mean systolic pressure after the administration was lowest in the test oil + ACEI group; the value in the test oil + ACEI group did not differ significantly compared with that in the test oil alone or ACEI alone group. This study also confirmed that ALA and ACEI have depressor effects. However, there were no synergistic effects of ALA and ACEI. The reason is unclear. Circulation is regulated via various mechanisms such as vasomotor regulation involving blood volume/vascular regulation, the regulation of heart function supporting changes in the 
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blood volume, and the kidney-mediated regulation of the body fluid volume and plasma osmotic pressure 19) . The combination of ALA and ACEI did not further decrease blood pressure. Because these mechanisms might function to avoid an excessive decrease in blood pressure, the combination of ALA and ACEI did not further decrease blood pressure.
The diastolic pressure showed no significant difference among the 3 groups before the administration ( ). Following administration, it decreased significantly only in the test oil + ACEI group compared with the level before the administration, but showed no significant difference among the 3 groups. These results suggest that the interaction between ALA and ACEI concerning the decrease in blood pressure is limited.
Bradykinin increases PGI 2 and NO with vasodilator activities via B 2 kinin receptors 20) . Sekine et al. 9) administered ALA to SHR and observed increases in the circulating bradykinin, PGI 2 metabolite, and NO metabolite levels. These results suggest that increases in vasodilators via bradykinin are involved in the depressor effect of ALA. Angiotensin-converting enzyme (ACE) converts angiotensin I to angiotensin II with a marked pressor activity. Since bradykinin is inactivated by ACE, ACEI increases the circulating bradykinin concentration. Shionoiri et al. demonstrated that the urinary excretion rate of kinins increased in patients with essential hypertension after a single dose of 10 mg of enalapril 21) . Campbell et al. 22) and Zeitz et al. 23) also showed that ACE inhibition increases bradykinin and kallidin levels in the arterial blood of human subjects. In this study, no significant difference was noted in the circulating bradykinin concentration after the administration of test oil and/or ACEI among the 3 groups ( ). These results suggest that the interaction between ALA and ACEI concerning the circulating bradykinin concentration is negligible or practically nonexistent.
We investigated the efficacy and risk of ALA-enriched oil in combination with ACEI. In this study, the combination of ALA-enriched oil and ACEI did not cause any rapid decrease in blood pressure. Therefore, the consumption of foods containing a large amount of ALA in combination with hypotensive agents may be safe. 
